Danube Pharmaceuticals Inc.

The more things change, the more they stay the same. The satirical 19th-century French critic Jean-Baptiste Alphonse Karr wasn't channeling ophthalmology when he authored that truism in 1849. But the

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology Start-ups aim for success by reprofiling older drugs or in-licensing candidates with safety track records. Blink, and you may miss it

Danube Pharmaceuticals Inc. Dual-mechanism oral glaucoma treatment c/o Two River Group Holdings 689 Fifth Avenue 12th Floor New York, NY 10022 Phone: (212) 871-7900 Fax: (212) 871-7901 Web Site: www.d